ClinicalTrials.gg
CompletedNCT06240351Updated Oct 30, 2026

A Study to Evaluate the Safety and Efficacy of Baricitinib in the Treatment of Frontal Fibrosing Alopecia (FFA)

A Phase 4 interventional study of Baricitinib 4 MG Oral Tablet in Frontal Fibrosing Alopecia, sponsored by University of Alabama at Birmingham. Completed at 1 site in United States. Open to female participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by University of Alabama at Birmingham · Phase 4, Interventional, and Treatment

How we know

Updated Oct 30, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 90 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 217 studies in Alopecia with a site in United States — 43 open to participants now, 63 under way, 6 of them phase 3. Alopecia · United States.

Enrollment
152nd of 204
20 · median 40
Started
2024
with 19 others
Phase 4
9 of 217
2 open now
Registered
168th of 217
by date

Among the 217 studies in Alopecia with a site in United States, this one is the 152nd largest by enrollment of the 204 interventional ones that give a count, is one of 20 that started in 2024, is one of 9 in phase 4, and was the 168th registered.

Alopecia

512 studies on the registry are indexed under Alopecia; 127 are open to participants now.

Browse Alopecia studies →

Open to participants now

43 of the 217 studies in Alopecia with a site in United States are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 75 Alopecia studies recruiting now, 24 (32%) set no upper age limit and 47 (63%) stop at 75 or younger; 10 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 90 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 217 studies in Alopecia with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the safety and efficacy of Baricitinib in the treatment of frontal fibrosing alopecia (FFA).

03

Conditions studied

  • Frontal Fibrosing Alopecia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female at least 18 years of age, and able to provide
  • Females who are defined, as not have menses for at least 12 months without an alternative medical cause and elevated follicle stimulating hormone in the postmenopausal range as measured during screening
  • Have active FFA that has been diagnosed on or prior to screening visit.
  • Have LPPAI score equal to or greater than 5 at screening.
  • Have evidence of eyebrow loss at baseline
  • Have evidence of hairline recession at baseline
  • Have classic presentation with frontal loss of scalp hair
  • Negative screening for tuberculosis (Quantiferon Gold, T-spot) within 3 months prior to screening or at the screening visit.
  • Agree not to have a during the study the exception is herpes zoster vaccine

Exclusion criteria

Exclusion Criteria:

  • Systemic treatments for FFA within 4 weeks of the baseline visit or 5 half lives whichever one is longer. (ex: finasteride, pioglitazone, hydroxychloroquine, or medications, such as mycophenolate mofetil).
  • Dutasteride within the last 6 months
  • Have a LPPAI score less than 5 at screening
  • Immunocompromised and with risk factors concerning to investigator for study participation
  • Previous treatment with an oral JAK inhibitor
  • Any condition in the opinion of the investigator which would interfere with the study assessments or procedure
  • Subject is pregnant or breast feeding
  • Surgical intervention including face lifts and micro-blading on the treatment areas
  • Any intervention (facelifts micro blading) that could affect the treatment areas (i.e. scalp and eyebrows)
  • Laser or phototherapy intervention on the treatment areas
  • Have evidence of active TB or latent TB
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Baricitinib

    All patients will be treated with the active product, Baricitinib. Each patient will take 4mg of Baricitinib daily for 36 weeks.

    Drug: Baricitinib 4 MG Oral Tablet

Interventions

06

What researchers measure

Primary outcomes

  1. 30% Change in Lichen Planopilaris Activity (LPPAI) Scores

    Percentage of patients achieving 30% change in LPPAI scores. LPPAI is a numeric scale that includes key signs and symptoms of FFA and allows for statistical comparison of disease activity. It captures patient reported symptoms (pruritus, pain, burning), clinical signs (erythema, perifollicular erythema, and scale), and other disease activity features (anagen pull and spreading). The total score distributes 30% weight to symptoms, 30% to signs, 25% to anagen pull, and 15% to spreading. The scale then ranges from 0-10 where 0 is no disease and 10 is worst disease.

    Time frame: From baseline to week 12, 24, and 36

Secondary outcomes

  1. Improvement in Physician Global Assessment (PGA)

    Effectiveness of Baricitinib on improvement in Patient Global Assessment.This assessment is a scale from 0 to 4. 0 means clear skin while 4 means severe disease.

    Time frame: From baseline to week 12, 24, and 36

  2. Change in inflammation on histology as seen on scalp biopsy

    Effectiveness of Baricitinib on change of inflammation results on histology exam as seen on scalp biopsy. Degree of lymphocytic infiltrate will be assessed on biopsy and compared to cast thickness on trichoscopy (which correlates with severity of inflammatory changes on pathology).

    Time frame: From baseline to week 12,24, and 36

  3. Improvement in trichoscopic grading of peripheral cast by way of Tosti Scale

    Effectiveness of Baricitinib on the improvement in trichoscopic grading of peripheral casts (scales). Degree of lymphocytic infiltrate will be assessed on biopsy and compared to cast thickness on trichoscopy by the Tosti Scale. This is a 3 grade measure with Grade 1 being minimum scaling while Grade 3 is maximum scaling.

    Time frame: From baseline to week 12,24, and 36

  4. Improvement in Eyebrow Assessment

    Effectiveness of Baricitinib on the improvement of the eyebrow assessment. This is a survey for patients to answer. Answers range from 0 to 3. Answers of 0 mean "I have full eyebrows on each side" while answers of 3 mean " I have no or barely any eyebrow hairs.

    Time frame: From baseline to week 12,24, and 36

  5. Improvement in Visual Analog Scale (VAS)

    Effectiveness of Baricitinib on the improvement of the Visual Analog Scale. This is a 10-point visual scale to rate whether the patient's FFA seems to be worse or resolved.

    Time frame: From baseline to week 12,24, and 36

07

Study locations

1 site
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Apr 2024 to primary completion in Sep 2026, 28 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: primary completion Oct 2026 → Sep 2026 and completion Sep 2027 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2024
First posted
Feb 5, 2024
StartActual
Apr 22, 2024
Primary completionActual
Sep 16, 2026was Oct 2026
CompletionActual
Sep 16, 2026was Sep 2027
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 30, 2026
Primary completion
Oct 31, 2026→Sep 16, 2026 (actual)
Oct 30, 2026
Study completion
Sep 30, 2027→Sep 16, 2026 (actual)
Oct 30, 2026
Enrollment
15 (estimated)→20 (actual)
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Active, not recruiting→Completed
    Primary completion Oct 31, 2026→Sep 16, 2026 (now actual)
    Study completion Sep 30, 2027→Sep 16, 2026 (now actual)
    Enrollment 15 (estimated)→20 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06240351
Responsible party
Boni Elewski (Professor, University of Alabama at Birmingham) — Principal investigator
First posted
Feb 5, 2024
Start date
Apr 22, 2024
Primary completion
Sep 16, 2026
Completion
Sep 16, 2026
Last update
Oct 30, 2026

Study contacts

Boni Elewski, MD
principal investigator · University of Alabama at Birmingham

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baricitinib

Start the discussion